A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)
Clinical trial NCT03162796 · COMPLETED
Trial details
- NCT number
- NCT03162796
- Sponsor
- Janssen Research & Development, LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-08-24
- Primary completion
- 2019-03-14
- Enrollment
- 383
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.